A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850

Background: Overexpression of metabotropic glutamate receptor 1 (GRM1) has been implicated in the pathogenesis of multiple cancers. Riluzole, an inhibitor of glutamate release, showed synergistic antitumor activity in combination with the multi-kinase inhibitor sorafenib in preclinical models. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Spencer, Kristen R., Portal, Daniella E., Aisner, Joseph, Stein, Mark N., Malhotra, Jyoti, Shih, Weichung, Chan, Nancy, Silk, Ann W., Ganesan, Shridar, Goodin, Susan, Gounder, Murugesan, Lin, Hongxia, Li, Jiadong, Cerchio, Robert, Marinaro, Christina, Chen, Suzie, Mehnert, Janice M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085060/
https://www.ncbi.nlm.nih.gov/pubmed/37036756
http://dx.doi.org/10.18632/oncotarget.28403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085060/
https://www.ncbi.nlm.nih.gov/pubmed/37036756
http://dx.doi.org/10.18632/oncotarget.28403

Ejemplares similares